Insmed (INSM) Competitors $97.12 +0.98 (+1.02%) As of 12:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INSM vs. REGN, ALNY, ARGX, BNTX, RPRX, BIIB, ILMN, GMAB, INCY, and EXELShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), argenex (ARGX), BioNTech (BNTX), Royalty Pharma (RPRX), Biogen (BIIB), Illumina (ILMN), Genmab A/S (GMAB), Incyte (INCY), and Exelixis (EXEL). These companies are all part of the "med - biomed/gene" industry. Insmed vs. Its Competitors Regeneron Pharmaceuticals Alnylam Pharmaceuticals argenex BioNTech Royalty Pharma Biogen Illumina Genmab A/S Incyte Exelixis Insmed (NASDAQ:INSM) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability. Do analysts recommend INSM or REGN? Insmed currently has a consensus target price of $108.07, suggesting a potential upside of 11.27%. Regeneron Pharmaceuticals has a consensus target price of $813.57, suggesting a potential upside of 48.86%. Given Regeneron Pharmaceuticals' higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Insmed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insmed 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00Regeneron Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.80 Which has more volatility and risk, INSM or REGN? Insmed has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Does the media favor INSM or REGN? In the previous week, Regeneron Pharmaceuticals had 25 more articles in the media than Insmed. MarketBeat recorded 33 mentions for Regeneron Pharmaceuticals and 8 mentions for Insmed. Insmed's average media sentiment score of 1.13 beat Regeneron Pharmaceuticals' score of 0.95 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 16 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Which has higher valuation and earnings, INSM or REGN? Regeneron Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInsmed$363.71M50.66-$913.77M-$5.95-16.32Regeneron Pharmaceuticals$14.20B4.15$4.41B$39.2813.91 Do institutionals & insiders have more ownership in INSM or REGN? 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 3.0% of Insmed shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is INSM or REGN more profitable? Regeneron Pharmaceuticals has a net margin of 31.94% compared to Insmed's net margin of -265.93%. Regeneron Pharmaceuticals' return on equity of 15.27% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets Insmed-265.93% -446.98% -52.70% Regeneron Pharmaceuticals 31.94%15.27%11.93% SummaryRegeneron Pharmaceuticals beats Insmed on 12 of the 17 factors compared between the two stocks. Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.42B$2.91B$5.53B$8.98BDividend YieldN/A2.45%5.25%4.04%P/E Ratio-16.3220.8927.0720.16Price / Sales50.66289.54430.62124.91Price / CashN/A41.1936.8257.86Price / Book60.707.728.075.57Net Income-$913.77M-$54.95M$3.17B$248.52M7 Day Performance-1.14%5.01%3.91%5.05%1 Month Performance37.41%4.38%3.63%6.98%1 Year Performance38.21%6.59%34.00%21.36% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed4.5542 of 5 stars$97.12+1.0%$108.07+11.3%+37.2%$18.42B$363.71M-16.321,271Positive NewsAnalyst ForecastREGNRegeneron Pharmaceuticals4.938 of 5 stars$525.00+0.8%$813.57+55.0%-47.9%$56.68B$14.20B13.3711,900Analyst RevisionALNYAlnylam Pharmaceuticals4.1206 of 5 stars$326.09+1.0%$340.00+4.3%+24.5%$42.52B$2.35B-156.022,000Positive NewsAnalyst ForecastARGXargenex4.3905 of 5 stars$551.22-1.6%$729.93+32.4%+23.4%$33.66B$2.58B34.00650Analyst UpgradeHigh Trading VolumeBNTXBioNTech1.442 of 5 stars$106.47-0.2%$137.86+29.5%+38.7%$25.59B$2.98B-31.313,080RPRXRoyalty Pharma4.8861 of 5 stars$36.03+0.4%$47.33+31.4%+38.1%$20.26B$2.26B19.4880Positive NewsBIIBBiogen4.9572 of 5 stars$125.59-0.4%$188.48+50.1%-41.0%$18.40B$9.68B12.407,605ILMNIllumina4.8669 of 5 stars$95.41+0.7%$127.39+33.5%-7.9%$15.10B$4.37B-15.729,030Positive NewsAnalyst ForecastGap DownGMABGenmab A/S4.0127 of 5 stars$20.66+0.8%$37.60+82.0%-16.6%$13.25B$3.12B11.742,682News CoverageAnalyst ForecastINCYIncyte4.7656 of 5 stars$68.10-0.4%$74.53+9.4%+16.3%$13.18B$4.24B212.822,617Insider TradeEXELExelixis4.7074 of 5 stars$44.08+0.9%$43.56-1.2%+97.0%$12.02B$2.17B20.041,147Analyst ForecastOptions Volume Related Companies and Tools Related Companies Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors argenex Competitors BioNTech Competitors Royalty Pharma Competitors Biogen Competitors Illumina Competitors Genmab A/S Competitors Incyte Competitors Exelixis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INSM) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
